S-1 in the treatment of pancreatic cancer
S-1 in the treatment of pancreatic cancer作者机构：Department of GastroenterologyChiba Cancer Center
出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)
年 卷 期：2014年第20卷第41期
页 面：15110-15118页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：Pancreatic cancer S-1 Chemotherapy Randomized controlled trial Chemoradiotherapy Adjuvant therapy
摘 要：S-1 is an oral 5-fluorouracil(5-FU) prodrug,which is designed to improve the antitumor activity of 5-FU by inhibiting dihydropyrimidine dehydrogenase,the key enzyme of 5-FU ***,two important studies on the clinical use of S-1 for pancreatic cancer have been reported from *** the first study(GEST study),S-1 demonstrated non-inferiority to gemcitabine(GEM) in overall survival(OS) for metastatic or locally advanced pancreatic cancer,but combination chemotherapy with GEM and S-1 did not show superiority to GEM in *** the second study(JASPAC-01 study),S-1 showed superiority to adjuvant chemotherapy with GEM in OS in patients with resected pancreatic *** addition to GEM,S-1 is now regarded as the key drug in the management of pancreatic cancer in *** date,many studies have investigated the effectiveness of S-1 in various settings,such as first-line chemotherapy for metastatic or locally advanced pancreatic cancer,second-line chemotherapy after GEM failure,and chemoradiotherapy for locally advanced *** this review,we focus on recent clinical trials of S-1-based chemotherapy for advanced pancreatic cancer.
维普期刊数据库